person · Reporting owner

Taich Adam

Disclosed activity across 2 companies

Tapewire entity: 19366
SEC CIK: 0001971187

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
10x Genomics, Inc.TXG · Entity 2172	Chief Financial Officer	September 09, 2026	September 11, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

10x Genomics, Inc.

Report date September 09, 2026 · Filed September 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	316,344	Ending reported balance After 2026-09-09 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2026-09-09 · Sale · Disposed 1,206 · Balance 361,526 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 10, 2026. F2: This transaction was executed in multiple trades at prices ranging from $63.67 to $63.83, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 2 · 2026-09-09 · Sale · Disposed 31,428 · Balance 330,098 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 10, 2026. F3: This transaction was executed in multiple trades at prices ranging from $64.01 to $64.87, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 3 · 2026-09-09 · Sale · Disposed 13,754 · Balance 316,344 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 10, 2026. F4: This transaction was executed in multiple trades at prices ranging from $64.88 to $65.875, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Filing footnotes · ownership attribution and instrument terms

F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 10, 2026.

F2: This transaction was executed in multiple trades at prices ranging from $63.67 to $63.83, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: This transaction was executed in multiple trades at prices ranging from $64.01 to $64.87, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $64.88 to $65.875, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

SomaLogic, Inc.

Report date January 05, 2024 · Filed January 09, 2024

Section 16 reporting ended · disclosed 2024-01-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-01-05 transaction · row 1 1 source row Row 1 · 2024-01-05 · Disposition to issuer · Disposed 48,425 · Balance 0 F1: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.27 · Expires 2031-11-09	Direct	Reported balance After 2024-01-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-01-05 · Disposition to issuer · Disposed 185,812 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F3: The option vested as to 1/4th of the total grant on November 10, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08 · Expires 2032-02-29	Direct	Reported balance After 2024-01-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-01-05 · Disposition to issuer · Disposed 110,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F5: The option vested as to 1/4th of the total grant on March 1, 2023, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.79 · Expires 2032-09-12	Direct	Reported balance After 2024-01-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-01-05 · Disposition to issuer · Disposed 145,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F6: The option vested as to 1/4th of the total grant on September 13, 2023, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2033-03-16	Direct	Reported balance After 2024-01-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-01-05 · Disposition to issuer · Disposed 150,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F7: The option vests as to 1/4th of the total grant on March 17, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.33 · Expires 2033-03-23	Direct	Reported balance After 2024-01-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-01-05 · Disposition to issuer · Disposed 95,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F8: The option vests as to 1/4th of the total grant on March 24, 2024, and thereafter 1/20th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.74 · Expires 2033-06-07	Direct	Reported balance After 2024-01-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-01-05 · Disposition to issuer · Disposed 855,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F9: The option vests as to 1/4th of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2024-01-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-01-05 · Disposition to issuer · Disposed 13,875 · Balance 0 F10: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F12: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F11: The RSUs vest as to 1/4th of the total grant on each of March 1, 2023, March 1, 2024, March 1, 2025 and March 1, 2026, subject to the continued service of the Reporting Person on each vesting date.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2024-01-05 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-01-05 · Disposition to issuer · Disposed 98,093 · Balance 0 F10: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F12: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F13: The RSUs vest as to 1/3rd of the total grant on each of September 13, 2023, September 13, 2024 and September 13, 2025, subject to the continued service of the Reporting Person on each vesting date.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2024-01-05 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2024-01-05 · Disposition to issuer · Disposed 53,250 · Balance 0 F10: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F12: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F14: The RSUs vest as to 1/4th of the total grant on each of September 13, 2023, September 13, 2024 and September 13, 2025 and September 13, 2026, subject to the continued service of the Reporting Person on each vesting date.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2024-01-05 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2024-01-05 · Disposition to issuer · Disposed 25,000 · Balance 0 F10: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F12: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F15: The RSUs vest as to 1/4th of the total grant on each of March 17, 2024, March 17, 2025, March 17, 2026 and March 17, 2027, subject to the continued service of the Reporting Person on each vesting date.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2024-01-05 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2024-01-05 · Disposition to issuer · Disposed 592,000 · Balance 0 F10: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F12: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F16: The RSUs vest as to 1/4th of the total grant on each of June 8, 2024, June 8, 2025, June 8, 2026 and June 8, 2027, subject to the continued service of the Reporting Person on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger").

F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock.

F3: The option vested as to 1/4th of the total grant on November 10, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.

F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions.

F5: The option vested as to 1/4th of the total grant on March 1, 2023, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.

F6: The option vested as to 1/4th of the total grant on September 13, 2023, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.

F7: The option vests as to 1/4th of the total grant on March 17, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.

F8: The option vests as to 1/4th of the total grant on March 24, 2024, and thereafter 1/20th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.

F9: The option vests as to 1/4th of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.

F10: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration.

F11: The RSUs vest as to 1/4th of the total grant on each of March 1, 2023, March 1, 2024, March 1, 2025 and March 1, 2026, subject to the continued service of the Reporting Person on each vesting date.

F12: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time.

F13: The RSUs vest as to 1/3rd of the total grant on each of September 13, 2023, September 13, 2024 and September 13, 2025, subject to the continued service of the Reporting Person on each vesting date.

F14: The RSUs vest as to 1/4th of the total grant on each of September 13, 2023, September 13, 2024 and September 13, 2025 and September 13, 2026, subject to the continued service of the Reporting Person on each vesting date.

F15: The RSUs vest as to 1/4th of the total grant on each of March 17, 2024, March 17, 2025, March 17, 2026 and March 17, 2027, subject to the continued service of the Reporting Person on each vesting date.

F16: The RSUs vest as to 1/4th of the total grant on each of June 8, 2024, June 8, 2025, June 8, 2026 and June 8, 2027, subject to the continued service of the Reporting Person on each vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 09, 2026 Filed Sep 11, 2026 20:47 UTC	10x Genomics, Inc. TXG · Entity 2172	SaleClass A Common Stock	13,754	$65.26	$897,550.28	Disclosure SEC source: 0001610717-26-000414 · form4.xml · nonDerivative · entry 3 Taich Adam · CIK 0001971187 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 316,344 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 10, 2026. F4 · price: This transaction was executed in multiple trades at prices ranging from $64.88 to $65.875, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document
September 09, 2026 Filed Sep 11, 2026 20:47 UTC	10x Genomics, Inc. TXG · Entity 2172	SaleClass A Common Stock	31,428	$64.31	$2,021,125.25	Disclosure SEC source: 0001610717-26-000414 · form4.xml · nonDerivative · entry 2 Taich Adam · CIK 0001971187 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 330,098 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 10, 2026. F3 · price: This transaction was executed in multiple trades at prices ranging from $64.01 to $64.87, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document
September 09, 2026 Filed Sep 11, 2026 20:47 UTC	10x Genomics, Inc. TXG · Entity 2172	SaleClass A Common Stock	1,206	$63.68	$76,794.94	Disclosure SEC source: 0001610717-26-000414 · form4.xml · nonDerivative · entry 1 Taich Adam · CIK 0001971187 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 361,526 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 10, 2026. F2 · price: This transaction was executed in multiple trades at prices ranging from $63.67 to $63.83, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document
August 24, 2026 Filed Aug 26, 2026 20:44 UTC	10x Genomics, Inc. TXG · Entity 2172	SaleClass A Common Stock	17,166	$63.02	$1,081,852.82	Disclosure SEC source: 0001610717-26-000391 · form4.xml · nonDerivative · entry 1 Taich Adam · CIK 0001971187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362,732 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document
May 22, 2026 Filed May 27, 2026 21:55 UTC	10x Genomics, Inc. TXG · Entity 2172	SaleClass A Common Stock	15,098	$24.44	$369,017.77	Disclosure SEC source: 0001610717-26-000162 · form4.xml · nonDerivative · entry 1 Taich Adam · CIK 0001971187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 379,898 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
February 26, 2026 Filed Mar 2, 2026 21:23 UTC	10x Genomics, Inc. TXG · Entity 2172	GrantClass A Common Stock	106,579	$0.00	$0.00	Disclosure SEC source: 0001610717-26-000075 · form4.xml · nonDerivative · entry 1 Taich Adam · CIK 0001971187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 394,996 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/12th of the RSUs shall vest on each quarterly anniversary measured from February 21, 2026, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
February 23, 2026 Filed Feb 25, 2026 21:51 UTC	10x Genomics, Inc. TXG · Entity 2172	SaleClass A Common Stock	8,968	$18.58	$166,593.16	Disclosure SEC source: 0001610717-26-000069 · form4.xml · nonDerivative · entry 1 Taich Adam · CIK 0001971187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,417 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
November 24, 2025 Filed Nov 25, 2025 22:24 UTC	10x Genomics, Inc. TXG · Entity 2172	SaleClass A Common Stock	11,888	$19.00	$225,851.79	Disclosure SEC source: 0001610717-25-000400 · form4.xml · nonDerivative · entry 1 Taich Adam · CIK 0001971187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 297,385 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
August 22, 2025 Filed Aug 26, 2025 20:14 UTC	10x Genomics, Inc. TXG · Entity 2172	SaleClass A Common Stock	22,315	$13.79	$307,656.91	Disclosure SEC source: 0001610717-25-000320 · form4.xml · nonDerivative · entry 1 Taich Adam · CIK 0001971187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 309,273 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
May 22, 2025 Filed May 27, 2025 21:06 UTC	10x Genomics, Inc. TXG · Entity 2172	SaleClass A Common Stock	4,044	$8.30	$33,562.37	Disclosure SEC source: 0001610717-25-000142 · form4.xml · nonDerivative · entry 1 Taich Adam · CIK 0001971187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,588 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
March 17, 2025 Filed Mar 19, 2025 21:34 UTC	10x Genomics, Inc. TXG · Entity 2172	GrantClass A Common Stock	133,928	$0.00	$0.00	Disclosure SEC source: 0001610717-25-000073 · form4.xml · nonDerivative · entry 2 Taich Adam · CIK 0001971187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,632 F2 · shares: Constitute RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/12th of the RSUs shall vest on each quarterly anniversary measured from February 21, 2025, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
October 23, 2024 Filed Mar 19, 2025 21:34 UTC	10x Genomics, Inc. TXG · Entity 2172	GrantClass A Common Stock	201,704	$0.00	$0.00	Disclosure SEC source: 0001610717-25-000073 · form4.xml · nonDerivative · entry 1 Taich Adam · CIK 0001971187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,704 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on August 21, 2024 and 1/16th of the RSUs shall vest on each quarterly anniversary thereafter for the following three years, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
January 05, 2024 Filed Jan 9, 2024 21:54 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerRestricted Stock Unit · Derivative	592,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-001334 · doc4.xml · derivative · entry 12 Taich Adam · CIK 0001971187 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 592,000 shares Expires not disclosed F10 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F12 · price: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F16 · derivative.exercise_date: The RSUs vest as to 1/4th of the total grant on each of June 8, 2024, June 8, 2025, June 8, 2026 and June 8, 2027, subject to the continued service of the Reporting Person on each vesting date. F16 · derivative.expiration_date: The RSUs vest as to 1/4th of the total grant on each of June 8, 2024, June 8, 2025, June 8, 2026 and June 8, 2027, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
January 05, 2024 Filed Jan 9, 2024 21:54 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerRestricted Stock Unit · Derivative	25,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-001334 · doc4.xml · derivative · entry 11 Taich Adam · CIK 0001971187 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F10 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F12 · price: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F15 · derivative.exercise_date: The RSUs vest as to 1/4th of the total grant on each of March 17, 2024, March 17, 2025, March 17, 2026 and March 17, 2027, subject to the continued service of the Reporting Person on each vesting date. F15 · derivative.expiration_date: The RSUs vest as to 1/4th of the total grant on each of March 17, 2024, March 17, 2025, March 17, 2026 and March 17, 2027, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
January 05, 2024 Filed Jan 9, 2024 21:54 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerRestricted Stock Unit · Derivative	53,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-001334 · doc4.xml · derivative · entry 10 Taich Adam · CIK 0001971187 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,250 shares Expires not disclosed F10 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F12 · price: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F14 · derivative.exercise_date: The RSUs vest as to 1/4th of the total grant on each of September 13, 2023, September 13, 2024 and September 13, 2025 and September 13, 2026, subject to the continued service of the Reporting Person on each vesting date. F14 · derivative.expiration_date: The RSUs vest as to 1/4th of the total grant on each of September 13, 2023, September 13, 2024 and September 13, 2025 and September 13, 2026, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
January 05, 2024 Filed Jan 9, 2024 21:54 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerRestricted Stock Unit · Derivative	98,093	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-001334 · doc4.xml · derivative · entry 9 Taich Adam · CIK 0001971187 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 98,093 shares Expires not disclosed F10 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F12 · price: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F13 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total grant on each of September 13, 2023, September 13, 2024 and September 13, 2025, subject to the continued service of the Reporting Person on each vesting date. F13 · derivative.expiration_date: The RSUs vest as to 1/3rd of the total grant on each of September 13, 2023, September 13, 2024 and September 13, 2025, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
January 05, 2024 Filed Jan 9, 2024 21:54 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerRestricted Stock Unit · Derivative	13,875	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-001334 · doc4.xml · derivative · entry 8 Taich Adam · CIK 0001971187 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,875 shares Expires not disclosed F10 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F12 · price: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F11 · derivative.exercise_date: The RSUs vest as to 1/4th of the total grant on each of March 1, 2023, March 1, 2024, March 1, 2025 and March 1, 2026, subject to the continued service of the Reporting Person on each vesting date. F11 · derivative.expiration_date: The RSUs vest as to 1/4th of the total grant on each of March 1, 2023, March 1, 2024, March 1, 2025 and March 1, 2026, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
January 05, 2024 Filed Jan 9, 2024 21:54 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerStock Option (Right to buy) · Derivative	855,000	Not disclosed Strike: $2.74	Not disclosed	Disclosure SEC source: 0001209191-24-001334 · doc4.xml · derivative · entry 7 Taich Adam · CIK 0001971187 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 855,000 shares Expires 2033-06-07 F4 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F9 · derivative.exercise_date: The option vests as to 1/4th of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
January 05, 2024 Filed Jan 9, 2024 21:54 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerStock Option (Right to buy) · Derivative	95,000	Not disclosed Strike: $2.33	Not disclosed	Disclosure SEC source: 0001209191-24-001334 · doc4.xml · derivative · entry 6 Taich Adam · CIK 0001971187 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 95,000 shares Expires 2033-03-23 F4 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F8 · derivative.exercise_date: The option vests as to 1/4th of the total grant on March 24, 2024, and thereafter 1/20th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
January 05, 2024 Filed Jan 9, 2024 21:54 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerStock Option (Right to buy) · Derivative	150,000	Not disclosed Strike: $2.30	Not disclosed	Disclosure SEC source: 0001209191-24-001334 · doc4.xml · derivative · entry 5 Taich Adam · CIK 0001971187 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2033-03-16 F4 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F7 · derivative.exercise_date: The option vests as to 1/4th of the total grant on March 17, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
January 05, 2024 Filed Jan 9, 2024 21:54 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerStock Option (Right to buy) · Derivative	145,000	Not disclosed Strike: $3.79	Not disclosed	Disclosure SEC source: 0001209191-24-001334 · doc4.xml · derivative · entry 4 Taich Adam · CIK 0001971187 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 145,000 shares Expires 2032-09-12 F4 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F6 · derivative.exercise_date: The option vested as to 1/4th of the total grant on September 13, 2023, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
January 05, 2024 Filed Jan 9, 2024 21:54 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerStock Option (Right to buy) · Derivative	110,000	Not disclosed Strike: $9.08	Not disclosed	Disclosure SEC source: 0001209191-24-001334 · doc4.xml · derivative · entry 3 Taich Adam · CIK 0001971187 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,000 shares Expires 2032-02-29 F4 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F5 · derivative.exercise_date: The option vested as to 1/4th of the total grant on March 1, 2023, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
January 05, 2024 Filed Jan 9, 2024 21:54 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerStock Option (Right to buy) · Derivative	185,812	Not disclosed Strike: $13.27	Not disclosed	Disclosure SEC source: 0001209191-24-001334 · doc4.xml · derivative · entry 2 Taich Adam · CIK 0001971187 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 185,812 shares Expires 2031-11-09 F4 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F3 · derivative.exercise_date: The option vested as to 1/4th of the total grant on November 10, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
January 05, 2024 Filed Jan 9, 2024 21:54 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerCommon Stock	48,425	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-001334 · doc4.xml · nonDerivative · entry 1 Taich Adam · CIK 0001971187 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. Read SEC document
September 15, 2023 Filed Oct 2, 2023 18:39 UTC	SomaLogic, Inc. SLGC · Entity 95310	SaleCommon Stock	21,584	$2.33	$50,286.40	Disclosure SEC source: 0001209191-23-051196 · doc4.xml · nonDerivative · entry 2 Taich Adam · CIK 0001971187 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,643 F1 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of Restricted Stock Units ("RSUs"). Read SEC document
June 08, 2023 Filed Jun 12, 2023 21:28 UTC	SomaLogic, Inc. SLGC · Entity 95310	GrantRestricted Stock Unit (RSU) · Derivative	592,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-036552 · doc4.xml · derivative · entry 2 Taich Adam · CIK 0001971187 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 592,000 Underlying: Common Stock · 592,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total grant on each of June 8, 2024, June 8, 2025, June 8, 2026 and June 8, 2027, subject to the continued service of the Reporting Person on each vesting date. F3 · derivative.expiration_date: The RSUs vest as to 1/4th of the total grant on each of June 8, 2024, June 8, 2025, June 8, 2026 and June 8, 2027, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
June 08, 2023 Filed Jun 12, 2023 21:28 UTC	SomaLogic, Inc. SLGC · Entity 95310	GrantEmployee Stock Option (Right to Buy) · Derivative	855,000	$0.00 Strike: $2.74	$0.00	Disclosure SEC source: 0001209191-23-036552 · doc4.xml · derivative · entry 1 Taich Adam · CIK 0001971187 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 855,000 Underlying: Common Stock · 855,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: The option vests as to 1/4 of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vest monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
March 02, 2023 Filed Oct 2, 2023 18:39 UTC	SomaLogic, Inc. SLGC · Entity 95310	SaleCommon Stock	1,412	$2.56	$3,611.33	Disclosure SEC source: 0001209191-23-051196 · doc4.xml · nonDerivative · entry 1 Taich Adam · CIK 0001971187 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,227 F1 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of Restricted Stock Units ("RSUs"). Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.